2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)

Background

Screen failures (SF) in early phase clinical trial are deleterious for patients, physicians and drug companies. It is therefore crucial to identify risk factors of SF, in order to optimize drug development and maximize patient’s benefit.

Methods

We created a self-assessment survey (SCITEP score) comprising 15 questions extracted from the ESAS, EQ-5D and PALLIA 10 scores, which evaluate patient’s (pts) symptoms and quality of life, each item being scored from 0 to 10 (i.e total score between 0 and 150). Patients entering a phase I clinical trial (ph1T) at Gustave Roussy cancer center between January 10^th and October 26^th 2022 were evaluated at screening (T0), and subsequently every month (T1, T2,..) until end of treatment.

Results

227 of 275 pts entering a Ph1T were assessed between January 10^th and October 26^th 2022. Most frequent tumor types were lung (18%), GI (16%), hematological (10%) and gynecological cancer (9.3%); 56% were female. At data cut off (January 15th 2023), 25 pts were considered SF. There was no difference observed between SF pts and pts who went on with the trial in terms of ECOG, RMH score, albumin and LDH levels, number of previous lines of treatments and of metastatic sites at baseline (Table). At T0, there was a significant difference in the SCITEP score between SF pts and the others (median score 41 [IQR 26-63] vs 20 [IQR 10-38], p<0.001). Internal validity of the score was good (cronbach alpha > 0.7). With a cutoff of ≥35, sensitivity of the survey to identify pts at high risk of SF was of 66.6% and specificity of 70.5%. Regarding overall survival, pts with a score ≥35 (n= 68) at T0 were at higher risk of death (survival rate at 3 months of 53% vs 65%, p<0.01). Table: 2158P

Conclusions

Self-assessment of risk of SF by pts entering a ph1T is feasible with the SCITEP score. A score ≥35 seemed associated with a higher risk of SF and of death at 3 months. Independent cohorts are needed to revalidate this score as a tool to better detect pts at risk of SF and thereby optimize drug development.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.